NEW YORK--(BUSINESS WIRE)--Demy-Colton’s BioFuture™ conference convenes trailblazers, disruptors, and forward-thinkers who are shaping the future of science and healthcare. BioFuture returns to New York City October 28-30 to explore the convergence of biopharma R&D, artificial intelligence, technology and healthcare delivery. This year’s conference will introduce the TechBio Showcase featuring innovators applying tech-first approaches to biopharma innovation in a transformative shift for the industry.
Taking place at Cure, New York City’s leading health innovation campus, BioFuture attracts more than 600 entrepreneurs, innovators, journalists and investors. Through company presentations, engaging plenary sessions, unfiltered interviews, workshops and networking, they will explore the new era of precision medicine, early disease intervention and the challenges and opportunities in vertical integration of healthcare systems. With the launch of TechBio Showcase this year, the conference will also explore drug discovery enabling technologies and tools, quantum computing, AI and machine learning enabled drug development, robotics and medical devices and biomanufacturing technologies among others.
Innovative public, private and seed companies are encouraged to submit an application to present at BioFuture. The Presenting Company Selection Committee seeks public and private companies developing new therapeutics as well as companies engaged in facilitating the discovery of new therapeutic technologies across biotech, techbio, digital medicine, healthtech, AI, machine learning and big data.
“BioFuture has always focused on creating the future of health by bringing together the best minds in biotech, healthcare delivery, science and technology. Collectively, we seek to explore how we can improve, innovate and advance new healthcare solutions for patients,” said Sara Demy, CEO and Founder of Demy-Colton. “We’re very excited about this year’s agenda and introducing TechBio Showcase. Technological advancements, favorable regulatory changes and a new strategic approach to research are fueling the emergence of this sector. We believe it will have a transformative impact in healthcare R&D and delivery.”
“TechBio is rapidly becoming one of the most significant catalysts for biological innovation,” said Daniella Kranjac, Founding GP at growth equity firm Avant Bio. “We’re at an important inflection point in the industry with the integration of AI, ML and other emerging tech across drug discovery, biomanufacturing and healthtech. Established leaders in the field are pursuing tech-first approaches while new players are capitalizing on an emerging opportunity to speed innovation and open new avenues while reducing risk and cost. With the introduction of the TechBio Showcase this year, BioFuture is not to be missed.”
For information on presentation or sponsorship opportunities, please contact Lila Taylor at ltaylor@demy-colton.com. For more information about BioFuture or to register, please visit www.biofuture.com and follow #BioFuture2024 on Twitter for the latest updates and discussions.
About Demy-Colton
Demy-Colton is a leading life sciences and digital health events organization, at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Biotech CEO Summit Europe™, Biotech CEO Summit in La Jolla, and Demy-Colton Virtual Salons. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders, where investment, learning, and thoughtful conversations thrive. For more information, visit www.demy-colton.com.
